Literature DB >> 35590003

Reversible lysine-targeted probes reveal residence time-based kinase selectivity.

Tangpo Yang1, Adolfo Cuesta1, Xiaobo Wan1,2, Gregory B Craven1, Brad Hirakawa3, Penney Khamphavong3, Jeffrey R May3, John C Kath3, John D Lapek3, Sherry Niessen3, Alma L Burlingame2, Jordan D Carelli3, Jack Taunton4.   

Abstract

The expansion of the target landscape of covalent inhibitors requires the engagement of nucleophiles beyond cysteine. Although the conserved catalytic lysine in protein kinases is an attractive candidate for a covalent approach, selectivity remains an obvious challenge. Moreover, few covalent inhibitors have been shown to engage the kinase catalytic lysine in animals. We hypothesized that reversible, lysine-targeted inhibitors could provide sustained kinase engagement in vivo, with selectivity driven in part by differences in residence time. By strategically linking benzaldehydes to a promiscuous kinase binding scaffold, we developed chemoproteomic probes that reversibly and covalently engage >200 protein kinases in cells and mice. Probe-kinase residence time was dramatically enhanced by a hydroxyl group ortho to the aldehyde. Remarkably, only a few kinases, including Aurora A, showed sustained, quasi-irreversible occupancy in vivo, the structural basis for which was revealed by X-ray crystallography. We anticipate broad application of salicylaldehyde-based probes to proteins that lack a druggable cysteine.
© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35590003     DOI: 10.1038/s41589-022-01019-1

Source DB:  PubMed          Journal:  Nat Chem Biol        ISSN: 1552-4450            Impact factor:   16.174


  38 in total

Review 1.  The resurgence of covalent drugs.

Authors:  Juswinder Singh; Russell C Petter; Thomas A Baillie; Adrian Whitty
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 2.  Developing irreversible inhibitors of the protein kinase cysteinome.

Authors:  Qingsong Liu; Yogesh Sabnis; Zheng Zhao; Tinghu Zhang; Sara J Buhrlage; Lyn H Jones; Nathanael S Gray
Journal:  Chem Biol       Date:  2013-02-21

3.  Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors.

Authors:  Brian A Lanman; Jennifer R Allen; John G Allen; Albert K Amegadzie; Kate S Ashton; Shon K Booker; Jian Jeffrey Chen; Ning Chen; Michael J Frohn; Guy Goodman; David J Kopecky; Longbin Liu; Patricia Lopez; Jonathan D Low; Vu Ma; Ana E Minatti; Thomas T Nguyen; Nobuko Nishimura; Alexander J Pickrell; Anthony B Reed; Youngsook Shin; Aaron C Siegmund; Nuria A Tamayo; Christopher M Tegley; Mary C Walton; Hui-Ling Wang; Ryan P Wurz; May Xue; Kevin C Yang; Pragathi Achanta; Michael D Bartberger; Jude Canon; L Steven Hollis; John D McCarter; Christopher Mohr; Karen Rex; Anne Y Saiki; Tisha San Miguel; Laurie P Volak; Kevin H Wang; Douglas A Whittington; Stephan G Zech; J Russell Lipford; Victor J Cee
Journal:  J Med Chem       Date:  2019-12-24       Impact factor: 7.446

4.  Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.

Authors:  Samuel E Dalton; Lars Dittus; Daniel A Thomas; Máire A Convery; Joao Nunes; Jacob T Bush; John P Evans; Thilo Werner; Marcus Bantscheff; John A Murphy; Sebastien Campos
Journal:  J Am Chem Soc       Date:  2018-01-09       Impact factor: 15.419

5.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 6.  Lysine-Targeted Inhibitors and Chemoproteomic Probes.

Authors:  Adolfo Cuesta; Jack Taunton
Journal:  Annu Rev Biochem       Date:  2019-01-11       Impact factor: 23.643

7.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

8.  Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.

Authors:  M Raymond V Finlay; Mark Anderton; Susan Ashton; Peter Ballard; Paul A Bethel; Matthew R Box; Robert H Bradbury; Simon J Brown; Sam Butterworth; Andrew Campbell; Christopher Chorley; Nicola Colclough; Darren A E Cross; Gordon S Currie; Matthew Grist; Lorraine Hassall; George B Hill; Daniel James; Michael James; Paul Kemmitt; Teresa Klinowska; Gillian Lamont; Scott G Lamont; Nathaniel Martin; Heather L McFarland; Martine J Mellor; Jonathon P Orme; David Perkins; Paula Perkins; Graham Richmond; Peter Smith; Richard A Ward; Michael J Waring; David Whittaker; Stuart Wells; Gail L Wrigley
Journal:  J Med Chem       Date:  2014-10-01       Impact factor: 7.446

9.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Authors:  Pasi A Jänne; James Chih-Hsin Yang; Dong-Wan Kim; David Planchard; Yuichiro Ohe; Suresh S Ramalingam; Myung-Ju Ahn; Sang-We Kim; Wu-Chou Su; Leora Horn; Daniel Haggstrom; Enriqueta Felip; Joo-Hang Kim; Paul Frewer; Mireille Cantarini; Kathryn H Brown; Paul A Dickinson; Serban Ghiorghiu; Malcolm Ranson
Journal:  N Engl J Med       Date:  2015-04-30       Impact factor: 91.245

10.  KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

Authors:  David S Hong; Marwan G Fakih; John H Strickler; Jayesh Desai; Gregory A Durm; Geoffrey I Shapiro; Gerald S Falchook; Timothy J Price; Adrian Sacher; Crystal S Denlinger; Yung-Jue Bang; Grace K Dy; John C Krauss; Yasutoshi Kuboki; James C Kuo; Andrew L Coveler; Keunchil Park; Tae Won Kim; Fabrice Barlesi; Pamela N Munster; Suresh S Ramalingam; Timothy F Burns; Funda Meric-Bernstam; Haby Henary; Jude Ngang; Gataree Ngarmchamnanrith; June Kim; Brett E Houk; Jude Canon; J Russell Lipford; Gregory Friberg; Piro Lito; Ramaswamy Govindan; Bob T Li
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 176.079

View more
  1 in total

1.  Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display.

Authors:  Mengmeng Zheng; Fa-Jie Chen; Kaicheng Li; Rahi M Reja; Fredrik Haeffner; Jianmin Gao
Journal:  J Am Chem Soc       Date:  2022-08-17       Impact factor: 16.383

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.